Eukaryotic expression vectors bearing genes encoding cytotoxic proteins for cancer gene therapy

Plasmid

Volumn 68, Issue 2, 2012, Pages 69-85

  Glinka, Elena M ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Cancer; Expression; Gene; Promoter; Toxic protein; Vector

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; APOLIPOPROTEIN E; BACULOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; CASPASE; CASPASE 8; CHORIONIC GONADOTROPIN; CYTOTOXIC FACTOR; DIPHTHERIA TOXIN; DIPHTHERIA TOXIN A; DOXORUBICIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 13 RECEPTOR ALPHA2; LENTIVIRUS VECTOR; MELITTIN; MESOTHELIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROSTATE SPECIFIC ANTIGEN; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; RAD51 PROTEIN; RIBOZYME; SERUM ALBUMIN; SOMATOMEDIN B; STREPTOLYSIN; STREPTOLYSIN O; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

APOPTOSIS; BLADDER TUMOR; CANCER GENE THERAPY; CANCER INHIBITION; CELL DEATH; COLON TUMOR; COLORECTAL CANCER; DNA RECOMBINATION; ENHANCER REGION; EXPRESSION VECTOR; GENE EXPRESSION; HUMAN; MALIGNANT ASCITES; NONHUMAN; OVARY CARCINOMA; OVARY TUMOR; PROMOTER REGION; PROSTATE CANCER; PROTEIN SYNTHESIS INHIBITION; REVIEW; SUICIDE GENE THERAPY; TRANSCRIPTION REGULATION; TRANSGENE; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; TOXINS, BIOLOGICAL;

EUKARYOTA; PSEUDOMONAS EXOTOXIN;

EID: 84863005720     PISSN: 0147619X     EISSN: 10959890     Source Type: Journal    
DOI: 10.1016/j.plasmid.2012.05.003     Document Type: Review

References (154)

1. Abdul-Ghani R., Ohana P., Matouk I., Ayesh S., Ayesh B., Laster M., Bibi O., Giladi H., Molnar-Kimber K., Sughayer M.A., De Groot N., Hochberg A. Use of Transcriptional Regulatory Sequences of Telomerase (hTER and hTERT). Mol. Ther. 2000, 2:539-544.
2. Agarwal S., Nikolai B., Yamaguchi T., Lech P., Somia N.V. Construction and use of retroviral vectors encoding the toxic gene barnase. Mol. Ther. 2006, 14:555-563.
3. Alexandrova R. Experimental strategies in gene therapy of cancer. J. Buon. 2009, 14:S23-S32.
4. Allured, V.S., Collier, R.J., Carrol, S.F., McCay, D.B., 1986. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc. Natl. Acad. Sci. USA 83, 1320-1324.
5. Amit D., Hochberg A. Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. J. Transl. Med. 2010, 8:134-152.
6. Amit D., Tamir S., Birman T., Gofrit O.N., Hochberg A. Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences. Int. J. Clin. Exp. Med. 2011, 4:91-102.
7. Ayesh S., Matouk I., Schneider T., Ohana P., Laster M., Al-Sharef W., De-Groot N., Hochberg A. The possible physiological role of H19 RNA. Mol. Carcinog. 2002, 35:63-74.
8. Ayesh B., Matouk I., Ohana P., Sughayer M.A., Birman T., Ayesh S., Schneider T., De Groot N., Hochberg A. Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. Mol. Ther. 2003, 7:535-541.
9. Beltinger C., Uckert W., Debatin K.-M. Suicide gene therapy for pediatric tumors. J. Mol. Med. 2001, 78:598-612.
10. Bertin S., Neves S., Pedroso de Lima M., Pierrefite-Carle V. Naked DNA and lipoplexes applications in cancer gene therapy. Bull. Cancer. 2007, 94:243-252.
11. Bhakdi S., Bayley H., Valeva A., Walev I., Walker B., Kehoe M., Palmer M. Staphylococcal α-toxin, streptolysin-O, and Escherichia coli hemolysin: prototypes of poreforming bacterial cytolysins. Arch. Microbiol. 1996, 165:73-79.
12. Boulaiz H., Prados J., Marchal J.A., García A.M., Alvarez L., Melguizo C., Carrillo E., Ramos J.L., Aránega A. Transfection of MS-36 melanoma cells with gef gene inhibits proliferation and induces modulation of the cell cycle. Cancer Sci. 2003, 94:564-568.
13. Boulaiz H., Prados J., Melguizo C., García A.M., Marchal J.A., Ramos J.L., Carrillo E., Vélez C., Aranega A. Inhibition of growth and induction of apoptosis in human breast cancer by transfection of gef gene. Br. J. Cancer 2003, 89:192-198.
14. Breidenbach M., Rein D.T., Everts M., Glasgow J.N., Wang M., Passineau M.J., Alvarez R.D., Korokhov N., Curiel D.T. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther. 2005, 12:187-193.
15. Candolfi M., Xiong W., Yagiz K., Liu C., Muhammad A.K., Puntel M., Foulad D., Zadmehr A., Ahlzadeh G.E., Kroeger K.M., Tesarfreund M., Lee S., Debinski W., Sareen D., Svendsen C.N., Rodriguez R., Lowenstein P.R., Castro M.G. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc. Natl. Acad. Sci. USA 2010, 107:20021-20026.
16. Cao G., Kuriyama S., Gao J., Mitoro A., Cui L., Nakatani T., Zhang X., Kikukawa M., Pan X., Fukui H., Qi Z. Comparison of carcinoembryonic antigen promoter regions isolated from human colorectal carcinoma and normal adjacent mucosa to induce strong tumor-selective gene expression. Int. J. Cancer 1998, 78:242-247.
17. Cao G.W., Qi Z.T., Pan X., Zhang X.Q., Miao X.H., Feng Y., Lu X.H., Kuriyama S., Du P. Gene therapy for human colorectal carcinoma using human CEA promoter contro led bacterial ADP-ribosylating toxin genes human CEA: PEA & DTA gene transfer. World J. Gastroenterol. 1998, 4:388-391.
18. Carlotti F., Zaldumbide A., Martin P., Boulukos K.E., Hoeben R.C., Pognonec P. Development of an inducible suicide gene system based on human caspase 8. Cancer Gene Ther. 2005, 12:627-639.
19. Choe S., Bennett M.J., Fugii G., Curmi P.M., Kantardjieff K.A., Collier R.J., Eisenberg D. The crystal structure of diphtheria toxin. Nature 1992, 357:216-222.
20. 2+ entry and subsequent apoptosis induced by melittin in human MG63 osteosarcoma cells. Life Sci. 2007, 80:364-369.
21. Collier R.J. Diphtheria toxin: mode of action and structure. Bacteriol. Rev. 1975, 39:54-85.
22. Collier R.J., Kandel J. Structure and activity of diphtheria toxin. J. Biol. Chem. 1971, 246:1496-1503.
23. Collins S.A., Guinn B.A., Harrison P.T., Scallan M.F., O'Sullivan G.C., Tangney M. Viral vectors in cancer immunotherapy: which vector for which strategy?. Curr. Gene Ther. 2008, 8:66-78.
24. Cong Y.S., Wen J., Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum. Mol. Genet. 1999, 8:137-142.
25. Crystal R.G. Transfer of genes to humans: early lessons and obstacles to success. Science 1995, 270:404-410.
26. Curtin J.F., Candolfi M., Puntel M., Xiong W., Muhammad A.K., Kroeger K., Mondkar S., Liu C., Bondale N., Lowenstein P.R., Castro M.G. Regulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators. Methods Mol. Biol. 2008, 434:239-266.
27. Dass C.R., Choong P.F. Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability. J. Control. Release 2006, 113:155-163.
28. Dobson J. Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene Ther. 2006, 13:283-287.
29. Doloff J.C., Jounaidi Y., Waxman D.J. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT. Cancer Gene Ther. 2011, 18:153-166.
30. Dong Z., Nör J.E. Transcriptional targeting of tumor endothelial cells for gene therapy. Adv. Drug Deliv. Rev. 2009, 2009(61):542-553.
31. Dorer D.E., Nettelbeck D.M. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv. Drug Deliv. Rev. 2009, 61:554-571.
32. Drazin R., Kandel J., Collier R.J. Structure and activity of diphtheria toxin. II. Attack by trypsin at a specific site within the intact toxin molecule. J. Biol. Chem. 1971, 246:1504-1510.
33. El-Aneed A. An overview of current delivery systems in cancer gene therapy. J. Control Release. 2004, 94:1-14.
34. Erdmann V.A., Barciszewska M.Z., Szymanski M., Hochberg A., de Groot N., Barciszewski J. The non-coding RNAs as riboregulators. Nucl. Acids Res. 2001, 29:189-193.
35. Feng J., Funk W.D., Wang S.S., Weinrich S.L., Avilion A.A., Chiu C.P., Adams R.R., Chang E., Allsopp R.C., Yu J., et al. The RNA component of human telomerase. Science 1995, 269:1236-1241.
36. Fernandes-Alnemri T., Takahashi A., Armstrong R., Krebs J., Fritz L., Tomaselli K.J., Wang L., Yu Z., Croce C.M., Salveson G., Earnshaw W.C., Litwack G., Alnemri E.S. Mch3, a novel human apoptotic cysteine protease highly related to CPP32. Cancer Res. 1995, 55:6045-6052.
37. Fitzgerald D., Pastan I. Pseudomonas exotoxin and recombinant immunotoxins derived from it. Ann. NY Acad. Sci. 1993, 685:740-745.
38. Fogar P., Navaglia F., Basso D., Zambon C.F., Moserle L., Indraccolo S., Stranges A., Greco E., Fadi E., Padoan A., Pantano G., Sanzari M.C., Pedrazzoli S., Montecucco C., Plebani M. Heat-induced transcription of diphtheria toxin A or its variants, CRM176 and CRM197: implications for pancreatic cancer gene therapy. Cancer Gene Ther. 2010, 17:58-68.
39. Foka P., Pourchet A., Hernandez-Alcoceba R., Doumba P.P., Pissas G., Kouvatsis V., Dalagiorgou G., Kazazi D., Marconi P., Foschini M., Manservigi R., Konstadoulakis M.M., Koskinas J., Epstein A.L., Mavromara P. Novel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors. J. Gene Med. 2010, 12:956-967.
40. Fu Y.G., Qu Y.J., Wu K.C., Zhai H.H., Liu Z.G., Fan D.M. Apoptosis-inducing effect of recombinant Caspase-3 expressed by constructed eukaryotic vector on gastric cancer cell line SGC7901. World J. Gastroenterol. 2003, 9:1935-1939.
41. Garver R.I., Goldsmith K.T., Rodu B., Hu P.C., Sorscher E.J., Curiel D.T. Strategy for achieving selective killing of carcinomas. Gene Ther. 1994, 1:46-50.
42. Gill D.M., Pappenheimer A.M. Structure-activity relationships in diphtheria toxin. J. Biol. Chem. 1971, 246:1492-1495.
43. Gill D.M., Dinius L.L. Observations on the structure of diphtheria toxin. J. Biol. Chem. 1971, 246:1485-1491.
44. Glinka E.M., Andryushchenko A.S., Sapozhnikov A.M., Zatsepina O.V. Construction of the plasmid for expression of ETA-EGFP fusion protein under control of the cytomegalovirus promoter and its effects in HeLa cells. Plasmid 2009, 62:119-127.
45. Goepfert C., Gazdhar A., Frey F.J., Frey B.M. Effect of electroporation-mediated diphtheria toxin A expression on PSA positive human prostate xenograft tumors in SCID mice. Prostate 2011, 71:872-880.
46. Hafkemeyer P., Brinkmann U., Gottesman M.M., Pastan I. Apoptosis induced by Pseudomonas exotoxin: a sensitive and rapid marker for gene delivery in vivo. Hum. Gene Ther. 1999, 10:923-934.
47. Hine C.M., Seluanov A., Gorbunova V. Use of the Rad51 promoter for targeted anti-cancer therapy. Proc. Natl. Acad. Sci. USA 2008, 105:20810-20815.
48. Hlavaty J., Jandl G., Liszt M., Petznek H., König-Schuster M., Sedlak J., Egerbacher M., Weissenberger J., Salmons B., Günzburg W.H., Renner M. Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma. J. Neurooncol. 2011, 102:59-69.
49. Hsu S., Qin H., Dickinson D., Xie D., Bollag W.B., Stoppler H., Pearl H., Vu A., Watkins M., Koehler M., Schuster G. Expression of caspase-14 reduces tumorigenicity of skin cancer cells. In Vivo. 2007, 21:279-283.
50. Huang Y.H., Zugates G.T., Peng W., Holtz D., Dunton C., Green J.J., Hossain N., Chernick M.R., Padera R.F., Langer R., Anderson D.G., Sawicki J.A. Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice. Cancer Res. 2009, 69:6184-6191.
51. Iglewski B.H., Kabat D. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin. Proc. Natl. Acad. Sci. USA 1975, 72:2284-2288.
52. Iglewski B.H., Liu P.V., Kabat D. Mechanism of action of Pseudomonas aeruginosa exotoxin A: adenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo. Infect. Immun. 1977, 15:138-144.
53. Jenkins C.E., Swiatoniowski A., Issekutz A.C., Lin T.J. Pseudomonas aeruginosa exotoxin A induces human mast cell apoptosis by a caspase-8 and -3-dependent mechanism. J. Biol. Chem. 2004, 279:37201-37207.
54. Kaneda Y., Tabata Y. Non-viral vectors for cancer therapy. Cancer Sci. 2006, 97:348-354.
55. Kaneda Y. Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool. Expert Opin. Drug Deliv. 2010, 7:1079-1093.
56. Kaur T., Slavcev R.A., Wettig S.D. Addressing the challenge: current and future directions in ovarian cancer therapy. Curr. Gene Ther. 2009, 9:434-458.
57. Kay M.A., Glorioso J.C., Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001, 7:33-40.
58. Keppler-Hafkemeyer A., Kreitman R.J., Pastan I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int. J. Cancer. 2000, 87:86-94.
59. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
60. Kimchi-Sarfaty C., Vieira W.D., Dodds D., Sherman A., Kreitman R.J., Shinar S., Gottesman M.M. SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice. Cancer Gene Ther. 2006, 13:648-657.
61. Knott A., Müller Y., Zunino S.J., Berens C., Hillen W. Conditional cell suicide using dox-dependent caspase-2 expression. J. Gene Med. 2003, 5:343-354.
62. Koga S., Hirohata S., Kondo Y., Komata T., Takakura M., Inoue M., Kyo S., Kondo S. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum. Gene Ther. 2000, 11:1397-1406.
63. Komata T., Kondo Y., Kanzawa T., Hirohata S., Koga S., Sumiyoshi H., Srinivasula S.M., Barna B.P., Germano I.M., Takakura M., Inoue M., Alnemri E.S., Shay J.W., Kyo S., Kondo S. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res. 2001, 61:5796-5802.
64. Komata T., Kondo Y., Kanzawa T., Ito H., Hirohata S., Koga S., Sumiyoshi H., Takakura M., Inoue M., Barna B.P., Germano I.M., Kyo S., Kondo S. Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Hum. Gene Ther. 2002, 13:1015-1025.
65. Koshikawa N., Takenaga K. Hypoxia-regulated expression of attenuated diphtheria toxin A fused with hypoxia-inducible factor-1alpha oxygen-dependent degradation domain preferentially induces apoptosis of hypoxic cells in solid tumor. Cancer Res. 2005, 65:11622-11630.
66. Koster F., Finas D., Schulz C., Hauser C., Diedrich K., Felberbaum R. Additive effect of steroids and cholesterol on the liposomal transfection of the breast cancer cell line T-47D. Int. J. Mol. Med. 2004, 14:769-772.
67. Kunitomi M., Takayama E., Suzuki S., Yasuda T., Tsutsui K., Nagaike K., Hiroi S., Tadakuma T. Selective inhibition of hepatoma cells using diphtheria toxin A under the control of the promoter/enhancer region of the human alpha-fetoprotein gene. Jpn. J. Cancer Res. 2000, 91:343-350.
68. Kwon B.S., Jung H.S., Song M.S., Cho K.S., Kim S.C., Kimm K., Jeong J.S., Kim I.H., Lee S.W. Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript. Mol. Ther. 2005, 12:824-834.
69. Lee E.J., Jameson J.L. Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy. Hum. Gene Ther. 2002, 13:533-542.
70. Leitner S., Sweeney K., Oberg D., Davies D., Miranda E., Lemoine N.R., Halldén G. Oncolytic adenoviral mutants with E1B19Kgene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin. Cancer Res. 2009, 15:1730-1740.
71. Li Y., McCadden J., Ferrer F., Kruszewski M., Carducci M., Simons J., Rodriguez R. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res. 2002, 62:2576-2582.
72. Li B., Gu W., Zhang C., Huang X.Q., Han K.Q., Ling C.Q. Growth arrest and apoptosis of the human hepatocellular carcinoma cell line BEL-7402 induced by melittin. Onkologie 2006, 29:367-371.
73. Li, B., Liu, X., Fan, J., Qi, R., Bo, L., Gu, J., Qian, Q., Qian, C., Liu, X., 2006. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo. J. Gene Med. 8, 1232-1242.
74. Lidor Y.J., Lee W.E., Nilson J.H., Maxwell I.H., Su L.J., Brand E., Glode L.M. In vitro expression of the diphtheria toxin A-chain gene under the control of human chorionic gonadotropin gene promoters as a means of directing toxicity to ovarian cancer cell lines. Am. J. Obstet. Gynecol. 1997, 177:579-585.
75. Ling C.Q., Li B., Zhang C., Zhu D.Z., Huang X.Q., Gu W., Li S.X. Inhibitory effect of recombinant adenovirus carrying melittin gene on hepatocellular carcinoma. Ann. Oncol. 2005, 16:109-115.
76. Lo H.W., Day C.P., Hung M.C. Cancer-specific gene therapy. Adv Genet. 2005, 54:235-255.
77. Lu Y. Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer. Adv. Drug Deliv. Rev. 2009, 61:572-588.
78. Lu Y., Madu C.O. Viral-based gene delivery and regulated gene expression for targeted cancer therapy. Expert. Opin. Drug Deliv. 2010, 7:19-35.
79. Marcelli M., Cunningham G.R., Walkup M., He Z., Sturgis L., Kagan C., Mannucci R., Nicoletti I., Teng B., Denner L. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res. 1999, 59:382-390.
80. Martin D.A., Siegel R.M., Zheng L., Lenardo M.J. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHalpha1) death signal. J. Biol. Chem. 1998, 273:4345-4349.
81. Martin V., Cortes M.L., de Felipe P., Farsetti A., Calcaterra N.B., Izquierdo M. Cancer gene therapy by thyroid hormone-mediated expression of toxin genes. Cancer Res. 2000, 60:3218-3224.
82. Massuda E.S., Dunphy E.J., Redman R.A., Schreiber J.J., Nauta L.E., Barr F.G., Maxwell I.H., Cripe T.P. Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells. Proc. Natl. Acad. Sci. USA 1997, 94:14701-14706.
83. Matouk I.J., DeGroot N., Mezan S., Ayesh S., Abu-lail R., Hochberg A., Galun E. The H19 non-coding RNA is essential for human tumor growth. PLoS One 2007, 2:e845-860.
84. Maxwell I.H., Maxwell F., Glode L.M. Regulated expression of a diphtheria toxin A - chain gene transfected into human cells: possible strategy for inducing cancer c ell suicide. Cancer Res. 1986, 46:4660-4664.
85. Maxwell I.H., Glode L.M., Maxwell F. Expression of the diphtheria toxin A-chain coding sequence under the control of promoters and enhancers from immunoglobulin genes as a means of directing toxicity to B-lymphoid cells. Cancer Res. 1991, 51:4299-4304.
86. Maxwell I.H., Glode L.M., Maxwell F. Expression of diphtheria toxin A-chain in mature B-cells: a potential approach to therapy of B-lymphoid malignancy. Leuk. Lymphoma. 1992, 7:457-462.
87. Maxwell I.H., Kaletta C., Naujoks K., Maxwell F. Targeting diphtheria toxin A-chain transcription to activated endothelial cells using an E-selectin promoter. Angiogenesis 2003, 6:31-38.
88. Miskimis R., Knapp L., Dewey M.J., Zhang X. Cell and tissue-specific expression of a heterologous gene under control of the myelin basic protein gene promoter in transgenic mice. Dev. Brain Res. 1992, 65:217-221.
89. Miura M., Zhu H., Rotello R., Hartwieg E.A., Yuan J. Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 1993, 75:653-660.
90. Mizrahi A., Czerniak A., Levy T., Amiur S., Gallula J., Matouk I., Abu-lail R., Sorin V., Birman T., de Groot N., Hochberg A., Ohana P. Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. J. Transl. Med. 2009, 7:69-80.
91. Mizrahi A., Czerniak A., Ohana P., Amiur S., Gallula J., Matouk I., Abu-Lail R., Birman T., Hochberg A., Levy T. Treatment of ovarian cancer ascites by intra-peritoneal injection of diphtheria toxin A chain-H19 vector: a case report. J. Med. Case Rep. 2010, 4:228-233.
92. Mizrahi A., Hochberg A., Amiur S., Gallula J., Matouk I., Birman T., Levy T., Ladimir S., Ohana P. Targeting diphtheria toxin and TNF alpha expression in ovarian tumors using the H19 regulatory sequences. Int. J. Clin. Exp. Med. 2010, 3:270-282.
93. Morissette G., Flamand L. Herpesviruses and chromosomal integration. J. Virol. 2010, 84:12100-12109.
94. Murayama Y., Tadakuma T., Kunitomi M., Kumai K., Tsutsui K., Yasuda T., Kitajima M. Cell-specific expression of the diphtheria toxin A-chain coding sequence under the control of the upstream region of the human alpha-fetoprotein gene. J Surg. Oncol. 1999, 70:145-149.
95. Nakamura T.M., Morin G.B., Chapman K.B., Weinrich S.L., Andrews W.H., Lingner J., Harley C.B., Cech T.R. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997, 277:955-959.
96. Niidome T., Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther. 2002, 9:1647-1652.
97. Oberg D., Yanover E., Adam V., Sweeney K., Costas C., Lemoine N.R., Halldén G. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin Cancer Res. 2010, 16:541-553.
98. Ohana P., Kopf E., Bibi O., Ayesh S., Schneider T., Laster M., Tykocinski M., de Groot N., Hochberg A. The expression of the H19 gene and its function in human bladder carcinoma cell lines. FEBS Lett. 1999, 454:81-84.
99. Ohana P., Bibi O., Matouk I., Levy C., Birman T., Ariel I., Schneider T., Ayesh S., Giladi H., Laster M., de Groot N., Hochberg A. Use of H19 regulatory sequences for targeted gene therapy in cancer. Int. J. Cancer 2002, 98:645-650.
100. Ohana P., Schachter P., Ayesh B., Mizrahi A., Birman T., Schneider T., Matouk I., Ayesh S., Kuppen P.J., de Groot N., Czerniak A., Hochberg A. Regulatory sequences of H19 and IGF2 genes in DNA-based therapy of colorectal rat liver metastases. J. Gene Med. 2005, 7:366-374.
101. Pang S., Dannull J., Kaboo R., Xie Y., Tso C.L., Michel K., deKernion J.B., Belldegrun A.S. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res. 1997, 57:495-499.
102. Pang S. Targeting and eradicating cancer cells by a prostate specific vector carrying the diphtheria toxin A gene. Cancer Gene Ther. 2000, 7:991-996.
103. Pappenheimer A.M. Diphtheria toxin. Annu. Rev. Biochem. 1977, 46:69-94.
104. Pastan I., Chaudhary V., FitzGerald D.J. Recombinant toxins as novel therapeutic agents. Annu. Rev. Biochem. 1992, 61:331-354.
105. Peng W., Verbitsky A., Bao Y., Sawicki J.A. Regulated expression of diphtheria toxin in prostate cancer cells. Mol. Ther. 2002, 6:537-545.
106. Peng W., Chen J., Huang Y.H., Sawicki J.A. Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells. Gene Ther. 2005, 12:1573-1580.
107. Phoenix D.A., Brandenburg K., Harris F., Seydel U., Hammerton T., Roberts I.S. An investigation into the membrane-interactive potential of the Escherichia coli KpsE C-terminus. Biochem. Biophys. Res. Commun. 2001, 285:976-980.
108. Poulsen L.K., Refn A., Molin S., Andersson P. Topographic analysis of the toxic gef protein from E. coli. Mol. Microbiol. 1991, 5:1639-1648.
109. Prados J., Melguizo C., Rama A., Ortiz R., Boulaiz H., Rodriguez-Serrano F., Caba O., Rodriguez-Herva J.J., Ramos J.L., Aranega A. Combined therapy using suicide gef gene and paclitaxel enhances growth inhibition of multicellular tumour spheroids of A-549 human lung cancer cells. Int. J. Oncol. 2008, 33:121-127.
110. Prados J., Melguizo C., Rama A.R., Ortiz R., Segura A., Boulaiz H., Vélez C., Caba O., Ramos J.L., Aránega A. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells. Cancer Chemother. Pharmacol. 2010, 66:69-78.
111. Prados J., Melguizo C., Ortiz R., Boulaiz H., Carrillo E., Segura A., Rodríguez-Herva J.J., Ramos J.L., Aránega A. Regression of established subcutaneous B16-F10 murine melanoma tumors after gef gene therapy associated with the mitochondrial apoptotic pathway. Exp. Dermatol. 2010, 19:363-371.
112. Quetglas J.I., Ruiz-Guillen M., Aranda A., Casales E., Bezunartea J., Smerdou C. Alphavirus vectors for cancer therapy. Virus Res. 2010, 153:179-196.
113. Robertson 3rd, M.W., Wang, M., Siegal, G.P., Rosenfeld, M., Ashford 2nd, R.S., Alvarez, R.D., Garver, R.I., Curiel, D.T., 1998. Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells. Cancer Gene Ther. 5, 331-336.
114. Robson T., Hirst D.G. Transcriptional targeting in cancer gene therapy. J. Biomed. Biotechnol. 2003, 2003:110-137.
115. Rothfels H., Paschen A., Schadendorf D. Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma. Exp. Dermatol. 2003, 12:799-810.
116. Rui H., Chen Y. Cell-specific expression of the diphtheria toxin A-chain coding sequence induces cancer cell suicide. Chin. Med. J. 2002, 115:869-873.
117. Scaiewicz V., Sorin V., Fellig Y., Birman T., Mizrahi A., Galula J., Abu-Lail R., Shneider T., Ohana P., Buscail L., Hochberg A., Czerniak A. Use of H19 gene regulatory sequences in DNA-based therapy for pancreatic cancer. J. Oncol. 2010, 178174-178184.
118. Schmidt M., Gruensfelder P., Roller J., Hagen R. Suicide gene therapy in head and neck carcinoma cells: an in vitro study. Int. J. Mol. Med. 2011, 27:591-597.
119. Seth P., Brinkmann U., Schwartz G.N., Katayose D., Gress R., Pastan I., Cowan K. Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging. Cancer Res. 1996, 56:1346-1351.
120. Shanker M., Jin J., Branch C.D., Miyamoto S., Grimm E.A., Roth J.A., Ramesh R. Tumor suppressor gene-based nanotherapy: from test tube to the clinic. J. Drug Deliv. 2011, 2011:465845-465855.
121. Shapira A., Benhar I. Toxin-based therapeutic approaches. Toxins 2010, 2:2519-2583.
122. Shatursky O., Heuck A.P., Shepard L.A., Rossjohn J., Parker M.W., Johnson A.E., Tweten R.K. The mechanism of membrane insertion for a cholesterol-dependent cytolysin: a novel paradigm for pore-forming toxins. Cell. 1999, 99:293-299.
123. Shibata M.A., Miwa Y., Miyashita M., Morimoto J., Abe H., Otsuki Y. Electrogene transfer of an Epstein-Barr virus-based plasmid replicon vector containing the diphtheria toxin A gene suppresses mammary carcinoma growth in SCID mice. Cancer Sci. 2005, 96:434-440.
124. Shinoura N., Koike H., Furitu T., Hashimoto M., Asai A., Kirino T., Hamada H. Adenovirus-mediated transfer of caspase-8 augments cell death in gliomas: implication for gene therapy. Hum. Gene Ther. 2000, 11:1123-1137.
125. Showalter S.L., Huang Y.H., Witkiewicz A., Costantino C.L., Yeo C.J., Green J.J., Langer R., Anderson D.G., Sawicki J.A., Brody J.R. Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells. Cancer Biol. Ther. 2008, 7:1584-1590.
126. Sierig G., Cywes C., Wessels M.R., Ashbaugh C.D. Cytotoxic effects of streptolysin O and streptolysin S enhance the virulence of poorly encapsulated group a streptococci. Infect. Immun. 2003, 71:446-455.
127. Simstein R., Burow M., Parker A., Weldon C., Beckman B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp. Biol. Med. (Maywood) 2003, 228:995-1003.
128. Song M.S., Lee S.W. Cancer-selective induction of cytotoxicity by tissue-specific expression of targeted trans-splicing ribozyme. FEBS Lett. 2006, 580:5033-5043.
129. Song Y., Shen K., Yu J.R. The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma. Zhonghua Yi Xue Za Zhi 2007, 87:2919-2924.
130. Song W., Dong Z., Jin T., Mantellini M.G., Núñez G., Nör J.E. Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells. Cancer Gene Ther. 2008, 15:667-675.
131. Srinivasula S.M., Ahmad M., MacFarlane M., Luo Z., Huang Z., Fernandes-Alnemri T., Alnemri E.S. Generation of constitutively active recombinant caspases-3 and -6 by rearrangement of their subunits. J. Biol. Chem. 1998, 273:10107-10111.
132. Tahara H., Yasui W., Tahara E., Fujimoto J., Ito K., Tamai K., Nakayama J., Ishikawa F., Tahara E., Ide T. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 1999, 18:1561-1567.
133. Takakura M., Kyo S., Kanaya T., Hirano H., Takeda J., Yutsudo M., Inoue M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcrip tional activation in immortalized and cancer cells. Clin. Cancer Res. 1999, 59:551-557.
134. Takeuchi H., Kanzawa T., Kondo Y., Komata T., Hirohata S., Kyo S., Kondo S. Combination of caspase transfer using the human telomerase reverse transcriptase promoter and conventional therapies for malignant glioma cells. Int. J. Oncol. 2004, 25:57-63.
135. Theimer C.A., Feigon J. Structure and function of telomerase RNA. Curr. Opin. Struct. Biol. 2006, 16:307-318.
136. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science 1998, 281:1312-1316.
137. Van den Bogaart G., Guzmán J.V., Mika J.T., Poolman B. On the mechanism of pore formation by melittin. J. Biol. Chem. 2008, 283:33854-33857.
138. Van der Poel H.G., McCadden J., Verhaegh G.W., Kruszewski M., Ferrer F., Schalken J.A., Carducci M., Rodriguez R. A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promoters. Cancer Gene Ther. 2001, 8:927-935.
139. Verma I.M., Somia N. Gene therapy-promises, problems and prospects. Nature 1997, 389:239-242.
140. Walton T., Wang J.L., Ribas A., Barsky S.H., Economou J., Nguyen M. Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector. Anticancer Res. 1998, 18:1357-1360.
141. Wang Y., Yuan F. Delivery of viral vectors to tumor cells: extracellular transport, systemic distribution, and strategies for improvement. Ann. Biomed. Eng. 2006, 34:114-127.
142. Wang Y., O'Malley B.W.J., Tsai S.Y., O'Malley B.W. A regulatory system for use in gene transfer. Proc. Natl. Acad. Sci. USA 1994, 91:8180-8184.
143. Wang C.Y., Li F., Yang Y., Guo H.Y., Wu C.X., Wang S. Recombinant baculovirus containing the diphtheria toxin A gene for malignant glioma therapy. Cancer Res. 2006, 66:5798-5806.
144. Wang G., Li G., Liu H., Yang C., Yang X., Jin J., Liu X., Qian Q., Qian W. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. J. Gene Med. 2009, 11:477-485.
145. Winder D., Günzburg W.H., Erfle V., Salmons B. Expression of antimicrobial peptides has an antitumour effect in human cells. Biochem. Biophys. Res. Commun. 1998, 242:608-612.
146. Wolf B.B., Green D.R. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J. Biol. Chem. 1999, 274:20049-20052.
147. Wolf P., Elsässer-Beile U. Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int. J. Med. Microbiol. 2009, 299:161-176.
148. Wu M., Kodani I., Dickinson D., Huff F., Ogbureke K.U., Qin H., Arun S., Dulebohn R., Al-Shabrawey M., Tawfik A., Prater S., Lewis J., Wataha J., Messer R., Hsu S. Exogenous expression of caspase-14 induces tumor suppression in human salivary cancer cells by inhibiting tumor vascularization. Anticancer Res. 2009, 29:3811-3818.
149. Xie X., Zhao X., Liu Y., Zhang J., Matusik R.J., Slawin K.M., Spencer D.M. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res. 2001, 61:6795-6804.
150. Yamabe K., Shimizu S., Ito T., Yoshioka Y., Nomura M., Narita M., Saito I., Kanegae Y., Matsuda H. Cancer gene therapy using a pro-apoptotic gene, caspase-3. Gene Ther. 1999, 6:1952-1959.
151. Yang W.S., Park S.O., Yoon A.R., Yoo J.Y., Kim M.K., Yun C.O., Kim C.W. Suicide cancer gene therapy using pore-forming toxin, streptolysin O. Mol. Cancer Ther. 2006, 5:1610-1619.
152. Yerushalmi N., Brinkmann U., Brinkmann E., Pai L., Pastan I. Attenuating the growth of tumors by intratumoral administration of DNA encoding Pseudomonas exotoxin via cationic liposomes. Cancer Gene Ther. 2000, 7:91-96.
153. Yu D., Chen D., Chiu C., Razmazma B., Chow Y.H., Pang S. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther. 2001, 8:628-635.
154. Zheng J.Y., Chen D., Chan J., Yu D., Ko E., Pang S. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A. Cancer Gene Ther. 2003, 10:764-770.